Tech Company Financing Transactions
Predicta Biosciences Funding Round
Predicta Biosciences, based in Boston, secured $23.4 million from Engine Ventures, Binney Street Capital and BrightEdge.
Transaction Overview
Company Name
Announced On
10/1/2025
Transaction Type
Venture Equity
Amount
$23,400,000
Round
Series A
Investors
Engine Ventures (Lead Investor) (ann DeWitt)
Proceeds Purpose
The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Predicta Biosciences is a precision oncology company integrating cutting-edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Our platform utilizes AI and cutting edge multi-omics technology to develop personalized treatment options for patients. We believe in empowering clinicians with the tools and knowledge they need to make informed decisions and provide the best care possible.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/1/2025: Zepto venture capital transaction
Next: 10/1/2025: Apricot Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs